ClinicalTrials.gg
RecruitingNCT07248865Updated Feb 20, 2026

A Phase 1 Study of CLYM116 in Normal Healthy Volunteers

A Phase 1 interventional study of CLYM116 and Placebo in Healthy Volunteers, sponsored by Climb Bio, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Climb Bio, Inc. · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Glomerulonephritis, IGA with a site in Australia — 10 open to participants now, 18 under way, 12 of them phase 3. Glomerulonephritis, IGA · Australia.

Planned enrollment
29th of 33
48 · median 155
Started
2025
with 4 others
Phase 1
Only one
of the 35
Primary completion
2026-07
later than 3 of 17 live
Registered
33rd of 35
by date

Among the 35 studies in Glomerulonephritis, IGA with a site in Australia, this one is the 29th largest by planned enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 1, reaches primary completion later than 3 of the 17 other live ones, and was the 33rd registered.

Glomerulonephritis, IGA

277 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

10 of the 35 studies in Glomerulonephritis, IGA with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glomerulonephritis, IGA with a site in Australia, or all of them as a file.
02

Study summary

This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.

Read the detailed description

CLYM116 is a humanized monoclonal antibody that selectively binds to a proliferation inducing ligand (APRIL). This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of CLYM116 in adult normal healthy volunteers (NHVs). The study will enroll up to 48 subjects, across up to five cohorts.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • CLYM116
  • APRIL
  • monoclonal antibody
  • healthy volunteers
  • Phase 1
  • IgA nephropathy
  • MIL116
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and females aged 18-60 years, inclusive
  • (BMI) between 18 and 32 kg/m² and weight between 45 and 110 kg
  • Clinically normal medical history, physical exam, , and laboratory results (or abnormalities deemed not )
  • Willing and able to comply with study procedures and provide
  • Women of must use highly effective and have negative pregnancy tests
  • Men must use contraception and refrain from sperm donation for 4 months post-dose
  • Completion of COVID-19 vaccination according to local guidelines, as well as influenza vaccination (within 12 months)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with drugs within 30 days or 5 half-lives
  • Previous or current hypogammaglobulinemia
  • Current presence of allergic reactions considered
  • Positive tests for , /C, syphilis, or tuberculosis
  • Tobacco use (>2 cigarettes/day), alcohol abuse, or drug abuse
  • Recent (within 21 days) or any non-live vaccine (within 14 days)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    CLYM116

    Subcutaneous (SC) injection of CLYM116

    Drug: CLYM116

  • Placebo comparator
    Placebo

    Subcutaneous (SC) injection of placebo

    Drug: Placebo

Interventions

  • DrugCLYM116

    CLYM116 to be administered by SC injection

  • DrugPlacebo

    Placebo solution to be administered at a matching volume by SC injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of single and multiple ascending doses of CLYM116 in healthy volunteers Incidence of treatment-emergent adverse events

    Time frame: From Screening through to Day 85, or final follow-up visit

  2. Incidence of injection site reactions Number of injection site reactions

    Time frame: From Baseline through to Day 4 and Day 15 to Day 18

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) Measurement of the maximum observed plasma concentration.

    Time frame: From Baseline through to Day 85 (except Day 14), or final follow-up visit

  2. Time to Maximum Observed Concentration (Tmax) Measurement of the time to maximum observed concentration.

    Time frame: From Baseline through to Day 85 (except Day 14), or final follow-up visit

  3. Area Under the Curve (AUC) Measurement of the area under the drug concentration-time curve.

    Time frame: From Baseline through to Day 85 (except Day 14), or final follow-up visit.

  4. Half-Life (T1/2) Measurement of the half-life in days

    Time frame: From Baseline through to Day 85 (except Day 14), or final follow-up visit

  5. Levels of Immunoglobulins Measurement of Immunoglobulins and changes over time

    Time frame: From Screening through to Day 85, or final follow-up visit

  6. Level of APRIL Measurement of APRIL in pg/mL and changes over time

    Time frame: Day -1, Baseline, Day 1, Day 4, Day 8, Day 14, Day 15, Day 17, Day 18, Day 22, Day 29, Day 71, day 85, final follow up visit

  7. Immunogenicity Measurement of CLYM116 antidrug antibodies (ADA)

    Time frame: Baseline, Day 15, Day 29, Day 43, Day 71, Day 85, follow-up visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2026, 7 months after the start.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Sep 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07248865
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Dec 2, 2025
Primary completion
Jul 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Climb Bio Study Director
Contact
clinicaltrials@climbbio.com
+1 866 857 2596

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion